BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Reddy VY, Akehurst RL, Armstrong SO, Amorosi SL, Beard SM, Holmes DR. Time to Cost-Effectiveness Following Stroke Reduction Strategies in AF: Warfarin Versus NOACs Versus LAA Closure. J Am Coll Cardiol. 2015;66:2728-2739. [PMID: 26616031 DOI: 10.1016/j.jacc.2015.09.084] [Cited by in Crossref: 60] [Cited by in F6Publishing: 37] [Article Influence: 8.6] [Reference Citation Analysis]
Number Citing Articles
1 Alkhouli M, Noseworthy PA, Rihal CS, Holmes DR. Stroke Prevention in Nonvalvular Atrial Fibrillation. Journal of the American College of Cardiology 2018;71:2790-801. [DOI: 10.1016/j.jacc.2018.04.013] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 7.3] [Reference Citation Analysis]
2 Pokorney SD, Mark DB. Cost-Effectiveness of Left Atrial Appendage Occlusion: A Case Based on Facts Not in Evidence? Circ Arrhythm Electrophysiol 2016;9:e004223. [PMID: 27307520 DOI: 10.1161/CIRCEP.116.004223] [Reference Citation Analysis]
3 Jackson LR 2nd, Jackson KP, Thomas KL. Percutaneous left atrial appendage occlusion: A review of current devices, clinical evidence, patient selection, and post procedural antithrombotic management. Prog Cardiovasc Dis 2021;66:92-100. [PMID: 34332665 DOI: 10.1016/j.pcad.2021.06.006] [Reference Citation Analysis]
4 Chao TF, Joung B, Takahashi Y, Lim TW, Choi EK, Chan YH, Guo Y, Sriratanasathavorn C, Oh S, Okumura K, Lip GYH. 2021 Focused Update Consensus Guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: Executive Summary. Thromb Haemost 2021. [PMID: 34773920 DOI: 10.1055/s-0041-1739411] [Reference Citation Analysis]
5 Freeman JV, Hutton DW, Barnes GD, Zhu RP, Owens DK, Garber AM, Go AS, Hlatky MA, Heidenreich PA, Wang PJ, Al-Ahmad A, Turakhia MP. Cost-Effectiveness of Percutaneous Closure of the Left Atrial Appendage in Atrial Fibrillation Based on Results From PROTECT AF Versus PREVAIL. Circ Arrhythm Electrophysiol 2016;9:e003407. [PMID: 27307517 DOI: 10.1161/CIRCEP.115.003407] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
6 Reddy VY, Gibson DN, Kar S, O'Neill W, Doshi SK, Horton RP, Buchbinder M, Gordon NT, Holmes DR. Post-Approval U.S. Experience With Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation. J Am Coll Cardiol. 2017;69:253-261. [PMID: 27816552 DOI: 10.1016/j.jacc.2016.10.010] [Cited by in Crossref: 132] [Cited by in F6Publishing: 91] [Article Influence: 22.0] [Reference Citation Analysis]
7 Reddy VY, Akehurst RL, Gavaghan MB, Amorosi SL, Holmes DR Jr. Cost-Effectiveness of Left Atrial Appendage Closure for Stroke Reduction in Atrial Fibrillation: Analysis of Pooled, 5-Year, Long-Term Data. J Am Heart Assoc 2019;8:e011577. [PMID: 31230500 DOI: 10.1161/JAHA.118.011577] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
8 Collado FMS, Lama von Buchwald CM, Anderson CK, Madan N, Suradi HS, Huang HD, Jneid H, Kavinsky CJ. Left Atrial Appendage Occlusion for Stroke Prevention in Nonvalvular Atrial Fibrillation. J Am Heart Assoc 2021;10:e022274. [PMID: 34668395 DOI: 10.1161/JAHA.121.022274] [Reference Citation Analysis]
9 Sharma SP, Park P, Lakkireddy D. Left Atrial Appendages Occlusion: Current Status and Prospective. Korean Circ J 2018;48:692-704. [PMID: 30073807 DOI: 10.4070/kcj.2018.0231] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
10 Joo H, Wang G, George MG. Age-specific Cost Effectiveness of Using Intravenous Recombinant Tissue Plasminogen Activator for Treating Acute Ischemic Stroke. Am J Prev Med 2017;53:S205-12. [PMID: 29153122 DOI: 10.1016/j.amepre.2017.06.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
11 Desai Y, El-Chami MF, Leon AR, Merchant FM. Management of Atrial Fibrillation in Elderly Adults. J Am Geriatr Soc 2017;65:185-93. [PMID: 27910092 DOI: 10.1111/jgs.14483] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
12 Yao Y, Shang MS, Dong JZ, Ma CS. Homocysteine in non-valvular atrial fibrillation: Role and clinical implications. Clin Chim Acta 2017;475:85-90. [PMID: 29050786 DOI: 10.1016/j.cca.2017.10.012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
13 Holmes DR, Alkhouli M, Reddy V. Left Atrial Appendage Occlusion for The Unmet Clinical Needs of Stroke Prevention in Nonvalvular Atrial Fibrillation. Mayo Clinic Proceedings 2019;94:864-74. [DOI: 10.1016/j.mayocp.2018.09.025] [Cited by in Crossref: 38] [Cited by in F6Publishing: 28] [Article Influence: 12.7] [Reference Citation Analysis]
14 Akin I, Nienaber CA. Left atrial appendage occlusion: A better alternative to anticoagulation? World J Cardiol 2017; 9(2): 139-146 [PMID: 28289527 DOI: 10.4330/wjc.v9.i2.139] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
15 Asmarats L, Rodés-cabau J. Percutaneous Left Atrial Appendage Closure: Current Devices and Clinical Outcomes. Circ Cardiovasc Interv 2017;10. [DOI: 10.1161/circinterventions.117.005359] [Cited by in Crossref: 42] [Cited by in F6Publishing: 7] [Article Influence: 8.4] [Reference Citation Analysis]
16 Yu J, Liu X, Zhou J, Xue X, Muenzel M, Schulze PC, Moebius-Winkler S, Keil T, Meng Z, Tang S. Long-term safety and efficacy of combined percutaneous LAA and PFO/ASD closure: a single-center experience (LAAC combined PFO/ASD closure). Expert Rev Med Devices 2019;16:429-35. [PMID: 30999776 DOI: 10.1080/17434440.2019.1604216] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
17 Ojo A, Yandrapalli S, Veseli G, Karim M, Aronow WS, Sharma M, Frishman WH, Naidu SS, Jacobson JT, Iwai S. Left Atrial Appendage Occlusion in the Management of Stroke in Patients With Atrial Fibrillation. Cardiol Rev 2020;28:42-51. [PMID: 30520738 DOI: 10.1097/CRD.0000000000000240] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 Lu S, Du X, Yang X, Jia Z, Li J, Xia S, Chang S, Zuo S, Guo X, Tang R, Sang C, Bai R, Zhou Y, Dong J, Ma C. Physical activity and atrial tachyarrhythmia recurrence in atrial fibrillation patients after catheter ablation. Pacing Clin Electrophysiol 2020;43:922-9. [PMID: 32638394 DOI: 10.1111/pace.14006] [Reference Citation Analysis]
19 Bergmann MW. LAA occluder device for stroke prevention: Data on WATCHMAN and other LAA occluders. Trends Cardiovasc Med 2017;27:435-46. [PMID: 28461140 DOI: 10.1016/j.tcm.2017.03.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
20 Chao TF, Joung B, Takahashi Y, Lim TW, Choi EK, Chan YH, Guo Y, Sriratanasathavorn C, Oh S, Okumura K, Lip GYH. 2021 Focused update of the 2017 consensus guidelines of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in atrial fibrillation. J Arrhythm 2021;37:1389-426. [PMID: 34887945 DOI: 10.1002/joa3.12652] [Reference Citation Analysis]
21 Alshehri AM. Stroke in atrial fibrillation: Review of risk stratification and preventive therapy. J Family Community Med 2019;26:92-7. [PMID: 31143079 DOI: 10.4103/jfcm.JFCM_99_18] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
22 Saw J, Bennell MC, Singh SM, Wijeysundera HC. Cost-Effectiveness of Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation Patients With Contraindications to Anticoagulation. Canadian Journal of Cardiology 2016;32:1355.e9-1355.e14. [DOI: 10.1016/j.cjca.2016.02.056] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
23 D'Ancona G, Arslan F, Safak E, Weber D, Al Ammareen R, Ince H. Actual management costs of patients with non-valvular atrial fibrillation treated with percutaneous left atrial appendage closure or oral anticoagulation. Int J Cardiol 2021:S0167-5273(21)02019-2. [PMID: 34929249 DOI: 10.1016/j.ijcard.2021.12.027] [Reference Citation Analysis]
24 Xue X, Jiang L, Duenninger E, Muenzel M, Guan S, Fazakas A, Cheng F, Illnitzky J, Keil T, Yu J. Impact of chronic kidney disease on Watchman implantation: experience with 300 consecutive left atrial appendage closures at a single center. Heart Vessels 2018;33:1068-75. [PMID: 29564543 DOI: 10.1007/s00380-018-1157-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
25 Lee VW, Tsai RB, Chow IH, Yan BP, Kaya MG, Park JW, Lam YY. Cost-effectiveness analysis of left atrial appendage occlusion compared with pharmacological strategies for stroke prevention in atrial fibrillation. BMC Cardiovasc Disord 2016;16:167. [PMID: 27581874 DOI: 10.1186/s12872-016-0351-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
26 Alipour A, Wintgens LI, Swaans MJ, Balt JC, Rensing BJ, Boersma LV. Novel stroke risk reduction in atrial fibrillation: left atrial appendage occlusion with a focus on the Watchman closure device. Vasc Health Risk Manag 2017;13:81-90. [PMID: 28293114 DOI: 10.2147/VHRM.S89213] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
27 Nédellec E, Pineau J, Prognon P, Martelli N. Level of Evidence in Economic Evaluations of Left Atrial Appendage Closure Devices: A Systematic Review. Appl Health Econ Health Policy 2018;16:793-802. [DOI: 10.1007/s40258-018-0429-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
28 Pérez de Prado A, Serrador A, Jiménez-Quevedo P, Benito González T, Fernández Vázquez F, Pan M. Selection of the Best of 2017 in Left Atrial Appendage Occlusion: Filling the Gap in Knowledge. Rev Esp Cardiol (Engl Ed) 2018;71:225-7. [PMID: 29352720 DOI: 10.1016/j.rec.2017.10.044] [Reference Citation Analysis]
29 Reddy VY, Akehurst RL, Amorosi SL, Gavaghan MB, Hertz DS, Holmes DR Jr. Cost-Effectiveness of Left Atrial Appendage Closure With the WATCHMAN Device Compared With Warfarin or Non-Vitamin K Antagonist Oral Anticoagulants for Secondary Prevention in Nonvalvular Atrial Fibrillation. Stroke 2018;49:1464-70. [PMID: 29739915 DOI: 10.1161/STROKEAHA.117.018825] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 4.3] [Reference Citation Analysis]
30 Morino Y, Nakajima Y. Structural heart intervention for prevention of embolic and hemorrhagic stroke: The new field of neurocardiology. J Cardiol 2020;76:227-35. [PMID: 32482326 DOI: 10.1016/j.jjcc.2020.04.007] [Reference Citation Analysis]
31 Dar T, Turagam MK, Yarlagadda B, Tantary M, Sheldon SH, Lakkireddy D. Indication, Patient Selection, and Referral Pathways for Left Atrial Appendage Closure. Interv Cardiol Clin 2018;7:169-83. [PMID: 29526286 DOI: 10.1016/j.iccl.2017.12.003] [Reference Citation Analysis]
32 Du X, Dong J, Ma C. Is Atrial Fibrillation a Preventable Disease? Journal of the American College of Cardiology 2017;69:1968-82. [DOI: 10.1016/j.jacc.2017.02.020] [Cited by in Crossref: 51] [Cited by in F6Publishing: 40] [Article Influence: 10.2] [Reference Citation Analysis]
33 Sahay S, Nombela-franco L, Rodes-cabau J, Jimenez-quevedo P, Salinas P, Biagioni C, Nuñez-gil I, Gonzalo N, de Agustín JA, del Trigo M, Perez de Isla L, Fernández-ortiz A, Escaned J, Macaya C. Efficacy and safety of left atrial appendage closure versus medical treatment in atrial fibrillation: a network meta-analysis from randomised trials. Heart 2017;103:139-47. [DOI: 10.1136/heartjnl-2016-309782] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
34 Reddy VY. Left atrial appendage closure devices: A reasonable therapeutic alternative. Heart Rhythm 2018;15:302-5. [PMID: 29030234 DOI: 10.1016/j.hrthm.2017.10.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
35 Estes NAM 3rd. Left Atrial Appendage Closure for Stroke Prevention in AF: The Quest for the Holy Grail. J Am Coll Cardiol 2015;66:2740-2. [PMID: 26616032 DOI: 10.1016/j.jacc.2015.10.019] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
36 Gloekler S, Saw J, Koskinas KC, Kleinecke C, Jung W, Nietlispach F, Meier B. Left atrial appendage closure for prevention of death, stroke, and bleeding in patients with nonvalvular atrial fibrillation. International Journal of Cardiology 2017;249:234-46. [DOI: 10.1016/j.ijcard.2017.08.049] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
37 Ong E, Meseguer E, Guidoux C, Lavallée PC, Hobeanu C, Charles H, Labreuche J, Cabrejo L, Martin-Bechet A, Rigual R, Nighoghossian N, Amarenco P. Prevalence and Outcome of Potential Candidates for Left Atrial Appendage Closure After Stroke With Atrial Fibrillation: WATCH-AF Registry. Stroke 2020;51:2355-63. [PMID: 32640939 DOI: 10.1161/STROKEAHA.120.029267] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
38 Mazzone P, Bella PD, Baratto F. Percutaneous left atrial appendage closure vs oral anticoagulation: The scariest might be the cheepest. International Journal of Cardiology 2022. [DOI: 10.1016/j.ijcard.2022.01.052] [Reference Citation Analysis]
39 Parashar A, Sud K, Devgun J, Agarwal S, Bassi M, Tuzcu EM, Griffin B, Krishnaswamy A, Kapadia S. Feasibility of LAA Closure for Left Atrial Thrombus in Patients With Aortic Stenosis and AF. Journal of the American College of Cardiology 2016;68:770-1. [DOI: 10.1016/j.jacc.2016.05.069] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
40 D Ancona G, Safak E, Weber D, Arslan F, Kische S, Darius H, Behrens S, Zohlenhöfer-Momm D, Ortak J, Kugler J, Ince H. Left atrial appendage closure with the watchman device reduces atrial fibrillation management costs. Clin Res Cardiol 2021. [PMID: 34652527 DOI: 10.1007/s00392-021-01943-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
41 Romero J, Avendano R, Diaz JC, Taveras J, Lupercio F, Di Biase L. Is it safe to stop oral anticoagulation after catheter ablation for atrial fibrillation? Expert Review of Cardiovascular Therapy 2018;17:31-41. [DOI: 10.1080/14779072.2019.1550718] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
42 Sanchez JM, Al-Dosari G, Chu S, Beygui R, Deuse T, Badhwar N, Lee RJ. Hybrid and surgical procedures for the treatment of persistent and longstanding persistent atrial fibrillation. Expert Rev Cardiovasc Ther 2018;16:91-7. [PMID: 29327638 DOI: 10.1080/14779072.2018.1425140] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
43 Caliskan E, Cox JL, Holmes DR, Meier B, Lakkireddy DR, Falk V, Salzberg SP, Emmert MY. Interventional and surgical occlusion of the left atrial appendage. Nat Rev Cardiol 2017;14:727-43. [DOI: 10.1038/nrcardio.2017.107] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 4.2] [Reference Citation Analysis]
44 Rocca DGD, Prete AD, Biase LD, Horton RP, Al-ahmad A, Bassiouny M, Mohanty S, Trivedi C, Romero J, Gianni C, Burkhardt JD, Gallinghouse GJ, Sanchez JE, Versaci F, Natale A; Texas Cardiac Arrhythmia Institute, St. David’s Medical Center, Austin, TX, USA, Division of Cardiology, S. Maria Goretti Hospital, Latina, Italy, Texas Cardiac Arrhythmia Institute, St. David’s Medical Center, Austin, TX, USA, Department of Internal Medicine, Dell Medical School, University of Texas, Austin, TX, USA, Department of Biomedical Engineering, Cockrell School of Engineering, University of Texas, Austin, TX, USA, Arrhythmia Services, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA, Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy, Texas Cardiac Arrhythmia Institute, St. David’s Medical Center, Austin, TX, USA, Texas Cardiac Arrhythmia Institute, St. David’s Medical Center, Austin, TX, USA, Texas Cardiac Arrhythmia Institute, St. David’s Medical Center, Austin, TX, USA, Texas Cardiac Arrhythmia Institute, St. David’s Medical Center, Austin, TX, USA, Texas Cardiac Arrhythmia Institute, St. David’s Medical Center, Austin, TX, USA, Arrhythmia Services, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA, Texas Cardiac Arrhythmia Institute, St. David’s Medical Center, Austin, TX, USA, Texas Cardiac Arrhythmia Institute, St. David’s Medical Center, Austin, TX, USA, Texas Cardiac Arrhythmia Institute, St. David’s Medical Center, Austin, TX, USA, Texas Cardiac Arrhythmia Institute, St. David’s Medical Center, Austin, TX, USA, Division of Cardiology, S. Maria Goretti Hospital, Latina, Italy, Texas Cardiac Arrhythmia Institute, St. David’s Medical Center, Austin, TX, USA, Department of Internal Medicine, Dell Medical School, University of Texas, Austin, TX, USA, Department of Biomedical Engineering, Cockrell School of Engineering, University of Texas, Austin, TX, USA, Interventional Electrophysiology, Scripps Clinic, La Jolla, CA, USA, Department of Cardiology, MetroHealth Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA, Division of Cardiology, Stanford University, Stanford, CA, USA. Current Endocardial Approaches for Left Atrial Appendage Closure. European Journal of Arrhythmia & Electrophysiology 2019;5:40. [DOI: 10.17925/ejae.2019.5.1.40] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
45 Suradi HS, Hijazi ZM. Left atrial appendage closure: outcomes and challenges. Neth Heart J 2017;25:143-51. [PMID: 27943175 DOI: 10.1007/s12471-016-0929-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
46 Pérez de Prado A, Serrador A, Jiménez-quevedo P, Benito González T, Fernández Vázquez F, Pan M. Selección de lo mejor del año 2017 en cierre percutáneo de la orejuela izquierda: completando la evidencia científica. Revista Española de Cardiología 2018;71:225-7. [DOI: 10.1016/j.recesp.2017.10.016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
47 Murtaza G, Boda U, Turagam MK, Della Rocca DG, Akella K, Gopinathannair R, Lakkireddy D. Risks and Benefits of Removal of the Left Atrial Appendage. Curr Cardiol Rep 2020;22:129. [PMID: 32910248 DOI: 10.1007/s11886-020-01387-x] [Reference Citation Analysis]
48 Salcedo J, Hay JW, Lam J. Cost-effectiveness of rivaroxaban versus warfarin for treatment of nonvalvular atrial fibrillation in patients with worsening renal function. Int J Cardiol 2019;282:53-8. [PMID: 30518479 DOI: 10.1016/j.ijcard.2018.11.087] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
49 Slaughter MS, Monreal G, Koenig SC, Giridharan GA, Tompkins LH, Jimenez JH. Demonstration of proof-of-concept of StrokeShield system for complete closure and occlusion of the left atrial appendage for non-valvular atrial fibrillation therapy. PLoS One 2021;16:e0253299. [PMID: 34157041 DOI: 10.1371/journal.pone.0253299] [Reference Citation Analysis]
50 D'Ancona G, Ince H. Rehospitalization and actual management costs after percutaneous left atrial appendage closure: Facing the conundrum. Int J Cardiol 2021;344:84-5. [PMID: 34600976 DOI: 10.1016/j.ijcard.2021.09.052] [Reference Citation Analysis]
51 Kupsky DF, Wang DD, Eng M, Gheewala N, Nakhle A, Georgie F, Shah R, Wyman J, Mahan M, Greenbaum A, O’neill WW. Socioeconomic Disparities in Access for Watchman Device Insertion in Patients with Atrial Fibrillation and at Elevated Risk of Bleeding. Structural Heart 2019;3:144-9. [DOI: 10.1080/24748706.2019.1569795] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
52 Rodwin BA, Desai NR. The Reply. Am J Med 2019;132:e723. [PMID: 31307679 DOI: 10.1016/j.amjmed.2019.05.029] [Reference Citation Analysis]